NMIL-12-1

N/A

Report date: 2023/12/31 20:00:33

Base Information

Drug NameNMIL-12-1
Drug Alias NameHemaMaxrHu-IL12Recombinant-human-interleukin-12 (Neumedicines)Recombinant-interleukin-12 (Neumedicines)rHuIL-12 (Neumedicines) +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunostimulantsInterleukin-12 receptor stimulants
TargetsInterleukin-12 receptor
Therapy Area/IndicationsAcute Radiation SyndromeSezary SyndromeMycosis Fungoides +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNeumedicines Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNeumedicines Inc
Active IndicationsN/A
Inactive IndicationsAcute Radiation SyndromeSezary SyndromeMycosis Fungoides +[5] 

Other Information

ATC CodeN/A
Related LinksN/A